Dossier assessment

Cefepime/enmetazobactam (bacterial infections, several therapeutic indications) – Assessment according to §35a (para. 1c) Social Code Book V

Report documents

2024-12-05 A G-BA decision was published.

Project no.: G24-15
Commission: Commission awarded on 13.06.2024 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Health Economics
Topic: Immune system and infections
Note: In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.
DOI: https://doi.org/10.60584/G24-15

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.